Evidence map›Paper›PMID 36850002›Full record

ArticleClinical epigenetics2023

Regulatory networks driving expression of genes critical for glioblastoma are controlled by the transcription factor c-Jun and the pre-existing epigenetic modifications.

Adria-Jaume Roura, Paulina Szadkowska, Katarzyna Poleszak, Michal J Dabrowski, Aleksandra Ellert-Miklaszewska, Kamil Wojnicki, Iwona A Ciechomska, Karolina Stepniak, Bozena Kaminska, Bartosz Wojtas

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Transcription-based comparison ofMicrobiology spectrum · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Adria-Jaume RouraLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Paulina SzadkowskaLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Katarzyna PoleszakLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Michal J DabrowskiInstitute of Computer Science of the Polish Academy of Sciences, Warsaw, Poland.
Aleksandra Ellert-MiklaszewskaLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Kamil WojnickiLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Iwona A CiechomskaLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Karolina StepniakLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Bozena KaminskaLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Bartosz WojtasLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland. b.wojtas@nencki.edu.pl.
Instytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLMedical University of Warsaw · PLPolish Academy of Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma (GBM, WHO grade IV) is an aggressive, primary brain tumor. Despite extensive tumor resection followed by radio- and chemotherapy, life expectancy of GBM patients did not improve over decades. Several studies reported transcription deregulation in GBMs, but regulatory mechanisms driving overexpression of GBM-specific genes remain largely unknown. Transcription in open chromatin regions is directed by transcription factors (TFs) that bind to specific motifs, recruit co-activators/repressors and the transcriptional machinery. Identification of GBM-related TFs-gene regulatory networks may reveal new and targetable mechanisms of gliomagenesis.

resultsWe predicted TFs-regulated networks in GBMs in silico and intersected them with putative TF binding sites identified in the accessible chromatin in human glioma cells and GBM patient samples. The Cancer Genome Atlas and Glioma Atlas datasets (DNA methylation, H3K27 acetylation, transcriptomic profiles) were explored to elucidate TFs-gene regulatory networks and effects of the epigenetic background. In contrast to the majority of tumors, c-Jun expression was higher in GBMs than in normal brain and c-Jun binding sites were found in multiple genes overexpressed in GBMs, including VIM, FOSL2 or UPP1. Binding of c-Jun to the VIM gene promoter was stronger in GBM-derived cells than in cells derived from benign glioma as evidenced by gel shift and supershift assays. Regulatory regions of the majority of c-Jun targets have distinct DNA methylation patterns in GBMs as compared to benign gliomas, suggesting the contribution of DNA methylation to the c-Jun-dependent gene expression.

conclusionsGBM-specific TFs-gene networks identified in GBMs differ from regulatory pathways attributed to benign brain tumors and imply a decisive role of c-Jun in controlling genes that drive glioma growth and invasion as well as a modulatory role of DNA methylation.

Indexed as

Brain NeoplasmsGlioblastomaGliomaChromatinDNA MethylationEpigenesis, GeneticHumansProto-Oncogene Proteins c-junChromatinProto-Oncogene Proteins c-junChromatin accessibilityDNA bindingDNA methylationGene expressionGlioblastomaTranscriptional deregulationTranscription factors

Identifiers

PMID36850002
PMCPMC9972689
OpenAlexW4322493910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.